Approvals of new chemical and biologic entities surged again in 2014, shepherded along by a confident FDA, as industry reaped the rewards of drug development incentives. Chris Morrison reports.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Hay, M., Thomas, D.W., Craighead, J.L., Economides, C. & Rosenthal, J. Nat. Biotechnol. 32, 40–51 (2014).
Kling, J. Nat. Biotechnol. 32, 121–124 (2014).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Morrison, C. Fresh from the biotech pipeline—2014. Nat Biotechnol 33, 125–128 (2015). https://doi.org/10.1038/nbt.3136
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.3136
